Immobilized Mouse Anti-MMAE&MMAF Antibody, Mouse IgG1 at 5 μg/mL, add Disitamab Vedotin (RC48) in the 50% Mouse serum and then add Biotinylated Human Her2, His,Avitag, premium grade at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (QC tested).
Immobilized ADC-MMAF at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 with a linear range of 0.5-1.56 ng/mL (Routinely tested).
Immobilized ADC-MMAF at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 with a linear range of 0.5-1.56 ng/mL (Routinely tested).
ELISA binding of Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 with Trastuzumab Deruxtecan, IgG1-MMAF, Sacituzumab Govitecam, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1, used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Trastuzumab Deruxtecan, IgG1-MMAF, Sacituzumab Govitecam, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (min X Bov, Hrs, Ms Sr Prot) (Jackson, Cat. No. 109-035-098) used at 1:12000 concentration.
Monoclonal Anti-MMAE&MMAF Antibody, Mouse IgG1 is specific to Disitamab Vedotin (RC48), Trastuzumab MMAE and IgG1-MMAF, and has no cross-reactivity with Trastuzumab Deruxtecan, Sacituzumab Govitecam and Trastuzumab-DM1 (Routinely tested).
